NCT05909215View on ClinicalTrials.gov

Attenuation Of Hemodynamic Response To Laryngoscopy. Role Of Dexmedetomidine. A Dose Finding Study

PHASE4CompletedINTERVENTIONAL
Enrollment

105

Participants

Timeline

Start Date

August 23, 2021

Primary Completion Date

December 13, 2021

Study Completion Date

December 13, 2021

Conditions
Hemodynamic InstabilityTracheal IntubationDexmedetomidine
Interventions
DRUG

Normal saline

Normal saline 20mL will be given intravenously through a syringe pump over 10 minutes

DRUG

Dexmedetomidine 0.5 microgram/kg

Dexmedetomidine 0.5 microgram/kg diluted in 20mL of normal saline will be given intravenously through a syringe pump over 10 minutes

DRUG

Dexmedetomidine 0.75 microgram/kg

Dexmedetomidine 0.75 microgram/kg diluted in 20mL of normal saline will be given intravenously through a syringe pump over 10 minutes

Trial Locations (1)

74200

Syed Muhammad Abbas, Karachi

All Listed Sponsors
lead

Sindh Institute of Urology and Transplantation

OTHER

NCT05909215 - Attenuation Of Hemodynamic Response To Laryngoscopy. Role Of Dexmedetomidine. A Dose Finding Study | Biotech Hunter | Biotech Hunter